Protalix BioTherapeutics (PLX) & Its Rivals Head-To-Head Comparison

Protalix BioTherapeutics (NYSE:PLX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Protalix BioTherapeutics to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Protalix BioTherapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0	0	1	0	3.00
Protalix BioTherapeutics Competitors	9838	15122	45436	1587	2.54

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 372.44%. As a group, “Biotechnology” companies have a potential upside of 102.58%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than its peers.

Insider & Institutional Ownership

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Protalix BioTherapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Protalix BioTherapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Risk & Volatility

Protalix BioTherapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics’ peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Valuation and Earnings

This table compares Protalix BioTherapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62 million	$8.31 million	11.04
Protalix BioTherapeutics Competitors	$733.29 million	$12.79 million	-15.19

Protalix BioTherapeutics’ peers have higher revenue and earnings than Protalix BioTherapeutics. Protalix BioTherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Protalix BioTherapeutics peers beat Protalix BioTherapeutics on 7 of the 13 factors compared.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.